Protagenic Therapeutics (PTIX) Price & Analysis

Compare

93 Followers

PTIX Stock Chart & Stats

$0.45

-$0.02(-2.65%)

At close: Jan 08 4:00 PM EST

$0.45

-$0.02(-2.65%)

Day’s Range― - ―

52-Week Range$0.25 - $14.28

Previous CloseN/A

Volume99.44K

Average Volume (3M)102.28K

Market Cap

$868.90K

Enterprise Value$1.25M

Total Cash (Recent Filing)$2.72M

Total Debt (Recent Filing)$3.16M

Price to Earnings (P/E)―

Beta-1.89

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-15.83

Shares Outstanding1,927,898

10 Day Avg. Volume80,054

30 Day Avg. Volume102,276

Financial Highlights & Ratios

PEG Ratio3.50

Price to Book (P/B)33.18

Price to Sales (P/S)0.00

P/FCF Ratio-7.97

Enterprise Value/Market Cap1.44

Enterprise Value/Revenue-49.63

Enterprise Value/Gross Profit-14.18

Enterprise Value/Ebitda-0.14

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressAdvancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.

Innovative Therapeutic ApproachA unique therapeutic mechanism can create a competitive advantage in treating CNS disorders, enhancing market position and long-term growth prospects.

Intellectual Property StrengthSecuring patents strengthens the company's intellectual property portfolio, protecting innovations and supporting long-term competitive positioning.

Bears Say

Financial InstabilityPersistent financial losses and lack of revenue highlight challenges in achieving financial stability, increasing reliance on external funding.

Negative Cash FlowNegative cash flow from operations indicates unsustainable financial practices, potentially limiting the company's ability to fund R&D and growth.

Deteriorating EquityDecreasing equity reflects weakening financial health, which could hinder the company's ability to invest in future growth opportunities.

Protagenic Therapeutics News

Protagenic Therapeutics Appoints William Nichols as President

Protagenic Therapeutics ( ($PTIX) ) has provided an announcement. On February 3, 2026, Protagenic Therapeutics, Inc. appointed William...

1d ago

PTIX

Protagenic Therapeutics Unwinds Phytanix Deal and Settles Litigation

Protagenic Therapeutics ( ($PTIX) ) has shared an announcement. On February 17, 2026, Protagenic Therapeutics, Inc. entered into...

8d ago

PTIX

Protagenic Therapeutics announces delay in quarterly filing

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has filed a...

14d ago

PTIX

Protagenic Therapeutics Prepares for Nasdaq Delisting, OTC Trading

Protagenic Therapeutics ( ($PTIX) ) just unveiled an announcement. On December 31, 2025, Protagenic Therapeutics received notice from...

2M ago

PTIX

Protagenic reports results from Phase 1 multiple-dose study of PT00114

Protagenic Therapeutics (PTIX) reported topline safety results from its Phase 1 Multiple Dose study of PT00114. PT00114 is...

3M ago

PTIX

Protagenic Therapeutics Faces Nasdaq Delisting Notice

Protagenic Therapeutics ( ($PTIX) ) just unveiled an announcement. On November 20, 2025, Protagenic Therapeutics received a notification...

3M ago

PTIX

Protagenic Therapeutics Delays Quarterly Report Filing

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has announced a...

4M ago

PTIX

Protagenic Therapeutics completes enrollment, dosing in Phase 1 MAD study

Protagenic Therapeutics (PTIX) announced the completion of enrollment and dosing in its Multiple Ascending Dose Phase 1 study...

4M ago

PTIX

Jennifer Chao Resigns from Protagenic Therapeutics Board

An announcement from Protagenic Therapeutics ( ($PTIX) ) is now available. On November 3, 2025, Jennifer Chao resigned...

4M ago

PTIX

Protagenic Therapeutics Seeks Rescission of Share Agreement

Protagenic Therapeutics ( ($PTIX) ) has shared an update. On October 28, 2025, Protagenic Therapeutics, Inc. filed a...

4M ago

PTIX

Protagenic Therapeutics Faces Nasdaq Compliance Notice

Protagenic Therapeutics ( ($PTIX) ) just unveiled an update. Protagenic Therapeutics is addressing a delay in filing its...

6M ago

PTIX

Protagenic advances PT00114 into multiple-dose Phase 1 trial

Protagenic Therapeutics (PTIX) announced completion of first dose injection for all study subjects in the multiple-dose portion of...

6M ago

PTIX

Protagenic Therapeutics Delays 10-Q Filing Amid Restructuring

Protagenic Therapeutics ( ($PTIX) ) has released a notification of late filing. Protagenic Therapeutics, Inc. has announced a...

7M ago

PTIX

Protagenic Therapeutics granted new patent in Japan for modified stilbenoid

Protagenic Therapeutics (PTIX) announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a...

7M ago

PTIX

PTIX FAQ

What was Protagenic Therapeutics’s price range in the past 12 months?

Protagenic Therapeutics lowest stock price was $0.25 and its highest was $14.28 in the past 12 months.

What is Protagenic Therapeutics’s market cap?

Protagenic Therapeutics’s market cap is $868.90K.

When is Protagenic Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Protagenic Therapeutics’s earnings last quarter?

Protagenic Therapeutics released its earnings results on Nov 16, 2021. The company reported -$2.8 earnings per share for the quarter, beating the consensus estimate of -$4.48 by $1.68.

Is Protagenic Therapeutics overvalued?

According to Wall Street analysts Protagenic Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Protagenic Therapeutics pay dividends?

Protagenic Therapeutics does not currently pay dividends.

What is Protagenic Therapeutics’s EPS estimate?

Protagenic Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Protagenic Therapeutics have?

Protagenic Therapeutics has 1,927,898 shares outstanding.

What happened to Protagenic Therapeutics’s price movement after its last earnings report?

Protagenic Therapeutics reported an EPS of -$2.8 in its last earnings report, beating expectations of -$4.48. Following the earnings report the stock price went down -2.874%.

Which hedge fund is a major shareholder of Protagenic Therapeutics?

Currently, no hedge funds are holding shares in PTIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Protagenic Therapeutics

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.